High loading of trimethylglycine promotes aqueous solubility of poorly water-soluble cisplatin

Riki Kadokawa1, Tetsuo Fujie1, Gyanendra Sharma1, Kojiro Ishibashi2, Kazuaki Ninomiya3, Kenji Takahashi1, Eishu Hirata2,4 & Kosuke Kuroda1

Trimethylglycine (TMG) is a cheap, natural, and highly biocompatible compound. Therefore, it has been used in the fields of food and life sciences, but the application of solid TMG is limited to utilisation as an “additive”. In the present study, we focused on the high solubility of TMG in water, derived from the aprotic zwitterionic structure, and proposed TMG as the chemical accounting for a major portion of the aqueous solution (e.g., 50 wt%). High loading of TMG shifted the properties of water and enabled the dissolution of poorly water-soluble cisplatin, an anticancer agent, at high concentration (solubility of cisplatin: 0.15 wt% in water vs 1.7 wt% in TMG aqueous solution). For hepatic arterial infusion, this can reduce the amount of cisplatin administered from 40 to 4 mL. It enables simple injection using a syringe, without the need for catheters and automatic pumps, leading to critical alleviation of the risk to patients. Furthermore, we produced a dry powder from a cisplatin-containing TMG aqueous solution via freeze-drying. Powders can be conveniently stored and transported. Furthermore, cisplatin is often used as a mixture with other drugs, and cisplatin aqueous solutions are not preferred as they dilute the other drugs.

Trimethylglycine (TMG) is present in various organisms and is especially rich in sugar beets. It is also the most commonly accumulated osmolyte in nature1–3. Therefore, TMG has been established as a low-price and highly biocompatible compound and used as an additive in food and cosmetic preparations. Furthermore, TMG has found application in life sciences as an additive, including as a polymerase chain reaction adjuvant4 and cryoprotective agent5. In other words, TMG has been employed as an additive to exert its functions in water as TMG is solid.

In the present study, we proposed the use of TMG to account for a major proportion of the aqueous solution (e.g., 50 wt%). TMG is a known natural aprotic zwitterion, presenting high water solubility owing to the charges, unlike most amino acids. High loading of TMG can drastically alter the nature of water, adding properties to water that cannot be realised by pure water or dilute aqueous solutions. Accordingly, the dissolution of poorly water-soluble drugs is a good candidate for these properties owing to the biocompatibility of TMG. Typically, the dissolution of poorly water-soluble drugs is achieved using organic solvents such as dimethyl sulfoxide (DMSO)6–10. However, organic solvents, including DMSO, are toxic and should be avoided in clinical and fundamental researches if possible11–14.

We employed a 50 wt% TMG aqueous solution (aq.) as a nearly saturated solution. In the present study, we used cisplatin as the poorly water-soluble platinum agent. Although cisplatin is a classical anticancer agent, it is used to treat certain cancer types such as triple-negative breast cancer. Dissolution of cisplatin in DMSO is especially avoided because chloride, as a ligand of cisplatin, is exchanged for DMSO, with the anticancer effect of cisplatin finally abolished10,15. Thus, we proposed a 50 wt% TMG aq. as an efficient cisplatin solvent without eliminating its anticancer effect.

1Faculty of Biological Science and Technology, Institute of Science and Engineering, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. 2Division of Tumor Cell Biology and Bioimaging, Cancer Research Institute of Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. 3Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. 4Nano Life Science Institute of Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. 5email: ehirata@staff.kanazawa-u.ac.jp; kkuroda@staff.kanazawa-u.ac.jp
Results and discussion

Cisplatin is poorly water-soluble, with marginal solubility (approximately 0.15 wt% [16]). The 50 wt% TMG aq. dissolved 1.7 wt% of cisplatin (Table 1). The diluted TMG solutions (25 and 5 wt%) dissolved less than 1.0 wt% of cisplatin, indicating that high loading of TMG is required to functionalise and dissolve cisplatin. High loading of L-carnitine, an analogous natural aprotic zwitterion, with a solubility of approximately 70 wt% in water, functionalised water, and the concentrated L-carnitine aq. dissolved cisplatin (Table 1). The 50 wt% TMG aq. dissolved cisplatin at an 11 times higher concentration than phosphate-buffered saline (PBS). Accordingly, the cisplatin solution administered to patients can be reduced to one-eleventh. For hepatic arterial infusion of cisplatin, 40–50 mL of a saturated cisplatin solution (0.15 wt%) is administered to a typical adult male using a catheter and an automatic pump. Theoretically, the highly concentrated cisplatin (1.7 wt%)/TMG solution reduces the amount to 4–5 mL, allowing injection using a syringe, without the need for catheters and automatic pumps, resulting in the critical alleviation of patient risk.

To discuss the dissolution mechanism of cisplatin in the TMG solution, the polarity of TMG was investigated. Ions have generally high polarity due to their positive- and negative charges. Since TMG does not have special functional groups, we considered the hydrogen bonding between TMG and cisplatin based on the high polarity should be a reason to solubilise. For solvents and organic ions, Kamlet-Taft parameters are generally used as indicators of the polarity [17,18]. In detail, $\beta$ value in the parameters exhibits the hydrogen bond basicity and the calculated $\beta$ value of TMG was 0.77. It is higher than that of water (around 0.15) [17], which does not dissolve cisplatin, and similar to that of cisplatin-dissolving DMSO (0.83) [18]. Therefore, the hydrogen bonding between carboxylate anion of TMG and ammonia ligand is considered to be a key factor to dissolve.

We confirmed that cisplatin dissolved in the 50 wt% TMG aq. retained its anticancer effects. The 50 wt% TMG aq. containing 10 mM cisplatin was prepared and added to human breast cancer cells (MDA-MB-231) at final concentrations ranging between 0.1 and 100 µM, by dilution in a culture medium. After incubation for 72 h, cell viability was measured and was decreased in a dose-dependent manner (Fig. 1). On employing DMSO as the solvent, the anticancer effect of cisplatin was abolished, as previously reported [10]. Furthermore, cisplatin dissolved in a 50 wt% L-carnitine aq. also retained the anticancer effect.

The ammonia ligand of cisplatin (Pt(NH$_3$)$_2$Cl$_2$) is stable, but the chloride ligand is exchangeable in the TMG aq. The replacement species are presumed to be water- or carboxylate-containing TMG. Cisplatin in the 50 wt% TMG aq. was measured using $^{195}$Pt NMR spectroscopy (Fig. 2). K$_2$[PtCl$_4$] was used in H$_2$O (~1628 ppm; −1.628 ppt in Fig. 2) [19,20] as a reference. A part of K$_2$[PtCl$_4$] was converted to K$_2$[PtCl$_3$(D$_2$O)] in D$_2$O, detected at −1196 ppm. Immediately after dissolution, Pt(NH$_3$)$_2$Cl$_2$ was observed at −2145 ppm in the 50 wt% TMG aq. The absence of other peaks suggests that ligand exchange did not occur. The solution was left at room temperature and evaluated on days 5 and 10. Although Pt(NH$_3$)$_2$Cl$_2$ was observed, another peak was observed at −1821 ppm, indicating that the chloride ligand was exchanged. When the integral value of the signal of Pt(NH$_3$)$_2$Cl$_2$ was fixed as 1.0, that of the emerging compound was 1.25 and 1.90 at days 5 and 10, respectively. The exchange proceeded over time, with 66 mol% of the chloride ligand exchanged after 10 days.

The emerging signal at −1821 ppm can be derived from either of the following compounds: [Pt(NH$_3$)$_2$Cl(TMGA)]$^+$, [Pt(NH$_3$)$_2$(TMGA)$_2$]$^{2+}$, [Pt(NH$_3$)$_2$Cl(H$_2$O)]$^+$, and [Pt(NH$_3$)$_2$(H$_2$O)$_2$]$^{2+}$. Herein, we performed mass spectrometry for the cisplatin-dissolved TMG aq.; however, none of them were detected owing to the extremely strong signal of excess TMG. Therefore, we measured cisplatin dissolved in water. Despite the low solubility (0.15 wt%), it is sufficient for performing mass spectrometry. A signal for [Pt(NH$_3$)$_2$Cl(H$_2$O)]$^+$ (m/z = 282) and a slight signal for [Pt(NH$_3$)$_2$(H$_2$O)$_2$]$^{2+}$ (m/z = 133) were detected (Fig. S1). Then, the same

| Content (wt%) | Solubility of cisplatin (wt%) |
|--------------|-------------------------------|
| TMG          |                               |
| 50           | 1.7                           |
| 25           | <1.0                          |
| 5            | <1.0                          |
| L-carnitine  |                               |
| 70           | 1.4                           |
| 50           | 1.0                           |
| 25           | <1.0                          |
| 5            | <1.0                          |
| Water$^*$    |                               |
|              | 0.15                          |

Table 1. Solubility of cisplatin in TMG or L-carnitine aqs. $^{*}$150 mM NaCl aq. at ambient temperature. The same solubility is shown in phosphate-buffered saline.

Scientific Reports | (2021) 11:9770 | https://doi.org/10.1038/s41598-021-89144-0
sample was subjected to $^{195}$Pt NMR spectroscopy (370,000 scans due to low solubility). A signal appeared at $-1839$ ppm, in addition to the signal for $\text{Pt(NH}_3\text{)}_2\text{Cl}_2$ ($-2148$ ppm) (Fig. S2). The new signal was assigned to $[\text{Pt(NH}_3\text{)}_2\text{Cl(H}_2\text{O)}]^+$, in accordance with the previous literature stating that signals for $[\text{Pt(NH}_3\text{)}_2\text{Cl(H}_2\text{O)}]^+$ and $[\text{Pt(NH}_3\text{)}_2\text{H}_2\text{O}_2]^{2+}$ in water appear at approximately $-1841^{21,22}$ and $-1567$ ppm$^{22,23}$, respectively. $[\text{Pt(NH}_3\text{)}_2\text{H}_2\text{O}_2]^{2+}$ observed by mass spectrometry was not detected by $^{195}$Pt NMR, presumably because of

Figure 1. MDA-MB-231 cell viability after treatment with cisplatin dissolved in the indicated solvents. (n = 3, biologically triplicated).

Figure 2. $^{195}$Pt NMR spectra of cisplatin dissolved in 50 wt% TMG aq. $\text{Pt(NH}_3\text{)}_2\text{Cl}_2$: $-2145$ ppm, $[\text{Pt(NH}_3\text{)}_2\text{Cl(H}_2\text{O)}]^+$: $-1821$ ppm. The x axis is shown in ppt. We used co-axial tubes and $K_2[\text{PtCl}_4]$ in D$_2$O was in the inner tube.
detection sensitivities and the low concentration of \([\text{Pt}(\text{NH}_3)_2(\text{H}_2\text{O})_2]^{2+}\). From these results, it was confirmed that chloride in cisplatin was exchanged not for TMG but for water in the 50 wt% TMG aq. after several days. 

\([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\) should scarcely enter cells owing to their positive charges\(^{24}\). Conversely, the anticancer effect was maintained in the 50 wt% TMG aq., as shown in Fig. 1. The ligand exchange between Cl\(^-\) and H\(_2\)O is known to be an equilibrium reaction\(^{25,26}\), and Cl\(^-\)-rich solutions can cause ligand re-exchange from \([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\) to \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\). In the experiment shown in Fig. 1, the initial stock solution was prepared as 10 mM cisplatin dissolved in 50 wt% TMG aq., and then it was diluted to the desired concentrations with the medium before treating MDA-MB-231 cells. Hence, NaCl contained in the medium is assumed to induce ligand re-exchange even in the presence of TMG.

Cisplatin was dissolved in 50 wt% TMG aq., and then left for 24 h. The ratios of \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) and \([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\) were 83 and 17 mol\%, respectively, as measured by \(^{195}\text{Pt}\) NMR (Fig. 3, day 1). Later, NaCl was additionally dissolved, and the ratio was evaluated on days 2–4. As expected, \([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\) decreased: the ratios at days 2, 3, and 4 were 2, 0, and 0 mol\%, respectively. Therefore, \([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\) reverted to \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) in the 50 wt% TMG aq. in the presence of NaCl.

For comparison, the same experiments were performed using a DMSO aq. \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) and \([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\) were not detected, and only \([\text{Pt}(\text{NH}_3)\text{Cl(DMSO)}]^{+}\) (− 3160 ppm)\(^{15}\) was detected on day 1. This trend was retained even after the addition of NaCl. A small amount of \([\text{Pt}(\text{NH}_3)\text{Cl}]^2\) (− 2115 ppm) was observed on day 3. This indicated that \([\text{Pt}(\text{NH}_3)\text{Cl(DMSO)}]^{+}\) in the DMSO aq. scarcely reverted to \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) in the presence of NaCl, unlike \([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\). Based on these results, although ligand exchange of \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) occurred in both the TMG aq. and DMSO (aq.), the replacing ligand species differed, which resulted in varying anticancer activities that were retained in the TMG aq. but not in DMSO.

The 50 wt% TMG aq. dissolved cisplatin at high concentrations and the resulting solution retained the anticancer effect of cisplatin. Herein, we proposed powderisation, as powders can be conveniently stored and transported. Furthermore, cisplatin is often used as a mixture with other drugs, and cisplatin aqueous solutions are undesirable as they dilute the other drugs. The 50 wt% TMG aq. containing 10 mM cisplatin was freeze-dried. The obtained powder was pale yellow, based on the colour of cisplatin. We regenerated 10 mM cisplatin-containing 50 wt% TMG aq. by adding the same amount of water to the powder to determine the anticancer effect. Then, the regenerated solution was added to MDA-MB-231 cells at final concentrations ranging between 0.1 and 100 µM. The regenerated cisplatin solution killed MDA-MB-231 cells in a dose-dependent manner (Fig. 4), indicating that freeze-drying did not affect the anticancer effect.

On dissolving the cisplatin/TMG powder, the powder was rapidly solubilised in water (Fig. S3). It requires only 60 s for dissolution whereas the typical dissolution of native cisplatin powder in 50 wt% TMG aq. required approximately 1 h. Therefore, the freeze-dried cisplatin/TMG powder is ready-to-use. Freeze-drying is considered an effective method for preparing rapidly soluble agents because resulting materials often have different crystallinities\(^{27}\). This could be a critical factor for rapid dissolution and TMG additionally might interfere the crystallisation of cisplatin. For hepatic arterial infusion, cisplatin-saturated PBS (0.15 wt%) is considered the state-of-the-art solution and needs to be heated at 50 °C to dissolve cisplatin. Conversely, the mixed powder was rapidly soluble at room temperature and could prepare an 11-fold concentrated cisplatin solution; the cisplatin/TMG powder is extremely promising for not only fundamental research but also clinical applications, including hepatic arterial infusion. Notably, TMG reportedly reduces nephrotoxicity when cisplatin is administered to mice\(^{28}\), and this effect could also be expected with the TMG aq.

In conclusion, the 50 wt% TMG aq. dissolved poorly water-soluble cisplatin. The solubility in 50 wt% TMG aq. was 1.7 wt%, which was 11 times that observed in water. Although the anticancer effect of cisplatin was abolished in DMSO, it was retained in the 50 wt% TMG aq. Furthermore, \(^{195}\text{Pt}\) NMR revealed that a portion of \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) was converted into \([\text{Pt}(\text{NH}_3)_2\text{Cl}(\text{H}_2\text{O})]^+\) in the 50 wt% TMG aq. On the other hand, the addition

---

**Figure 3.** Ratio of \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) and the substituted compounds after dissolution in 50 wt% TMG aq. or equimolar DMSO aq., followed by NaCl addition. *The peak of \([\text{Pt}(\text{NH}_3)_2\text{Cl}]^2\) on day 3 in DMSO aq. was observed in only one of the three samples.
of NaCl induced ligand exchange from \(\text{[Pt(NH}_3\text{)}_2\text{Cl(H}_2\text{O})]^+\) to Pt(NH\(_3\))\(_2\)Cl\(_2\). As the medium used in this study contained NaCl, this ligand re-exchange was assumed to occur in the presence of TMG. Moreover, the 50 wt% TMG aq. containing 10 mM cisplatin was freeze-dried. The resulting powder was rapidly solubilised at room temperature; this has not been achieved with conventional cisplatin powders.

Received: 16 February 2021; Accepted: 16 April 2021
Published online: 07 May 2021

References
1. Yancey, P. H. & Burg, M. B. Counteracting effects of urea and betaine in mammalian cells in culture. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **258**, R198–R204 (1990).
2. Robertson, D. E., Noll, D., Roberts, M., Menaia, J. & Boone, D. Detection of the osmoregulator betaine in methanogens. *Appl. Environ. Microbiol.* **56**, 563–569 (1990).
3. Cayley, S. & Record, M. T. Roles of cytoplasmic osmolytes, water, and crowding in the response of *Escherichia coli* to osmotic stress: biophysical basis of osmoprotection by glycine betaine. *Biochemistry* **42**, 12596–12609 (2003).
4. Henke, W., Herdel, K., Jung, K., Schnorr, D. & Loening, S. A. Betaine improves the PCR amplification of GC-rich DNA sequences. *Nucleic Acids Res.* **25**, 3957–3958 (1997).
5. Yang, J. et al. Natural zwitterionic betaine enables cells to survive ultrarapid cryopreservation. *Sci. Rep.* **6**, 37458 (2016).
6. de Mattos, S. F., Villalonga, P., Clardy, J. & Lam, E. W. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. *Mol. Cancer Ther.* **7**, 3237–3246 (2008).
7. Eberle, K. E., Sansing, H. A., Stannielo, P., Resto, V. A. & Berrier, A. L. Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-κB. *PLoS ONE* **6**, e21496 (2011).
8. Chen, Y.-J., Shen, M.-R., Chen, Y.-J., Maa, M.-C. & Leu, T.-H. Eps8 decreases chemosensitivity and affects survival of cervical cancer patients. *Mol. Cancer Ther.* **7**, 1376–1385 (2008).
9. Augustin-Rauch, K. A., Zhang, Q., Kleinman, M., Lawton, R. & Welsh, M. J. A study of vehicles for dosing rodent whole embryo culture with non aqueous soluble compounds. *Reprod. Toxicol.* **18**, 391–398 (2004).
10. Hall, M. D. et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. *Cancer Res.* **74**, 3913–3922 (2014).
11. Verheijen, M. et al. DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. *Sci. Rep.* **9**, 1–12 (2019).
12. Kang, M.-H. et al. The cytotoxic effects of dimethyl sulfoxide in mouse preimplantation embryos: a mechanistic study. *Theranostics* **7**, 4735 (2017).
13. Tunçer, S. et al. Low dose dimethyl sulfoxide driven gross molecular changes have the potential to interfere with various cellular processes. *Sci. Rep.* **12**, 14828 (2018).
14. Thaler, R., Spitzer, S., Karlic, H., Klaushofer, K. & Varga, F. DMSO is a strong inducer of DNA hydroxymethylation in pre-osteoblastic MC3T3-E1 cells. *Epigenetics* **7**, 635–651 (2012).
15. Kerrison, S. J. S. & Sadler, P. J. Solvolysis of cis-[Pt(NH\(_3\))\(_2\)Cl\(_2\)] in dimethyl sulfoxide and reactions of glycine with [PtCl\(_3\)(Me\(_2\)SO)] as probed by \(^{195}\text{Pt}^\text{nuclear magnetic resonance shifts and }^{195}\text{Pt}^{--}\text{N}^\text{coupling constants. J. Chem. Soc. Chem. Commun.} **23**, 861–863 (1977).
16. Woo, J. et al. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. *Int. J. Pharm.* **349**, 38–46 (2008).
17. Lu, J., Brown, J. S., Liotta, C. L. & Eckert, C. A. Polarity and hydrogen-bonding of ambient to near-critical water: Kamlet–Taft solvent parameters. *Chem. Commun.* **6**, 665–666 (2001).
18. Satria, H., Kuroda, K., Tsuge, Y., Ninomiya, K. & Takahashi, K. Dimethyl sulfoxide enhances both the cellulose dissolution ability and biocompatibility of a carboxylate-type liquid zwitterion. *New J. Chem.* **42**, 13225–13228 (2018).
19. Freeman, W., Pregosin, P. S., Sze, S. N. & Venanzi, L. M. Platinum-195NMR using Fourier transform techniques. The PtCl\(_4^--\)ion. *J. Magn. Reson.* **22**, 473–478 (1976).
20. Murray, P. & Koch, K. R. A. \(^{195}\text{Pt}^\text{NMR study of the oxidation of }[\text{PtCl}_4^--\text{] with chlorate, bromate, and hydrogen peroxide in acidic aqueous solution. J. Coord. Chem.} **63**, 2561–2577 (2010).
21. Bancroft, D. P., Lepre, C. A. & Lippard, S. J. Platinum-\(^{195}\)NMR kinetic and mechanistic studies of cis- and trans-diaminedichloroplatinum (II) binding to DNA. *J. Am. Chem. Soc.* **112**, 6860–6871 (1990).
22. Appleton, T. G., Hall, J. R. & Ralph, S. \(^{15}N\) and \(^{195}Pt\) NMR spectra of platinum ammine complexes: trans- and cis-influence series based on \(^{195}Pt\)\(^{15}N\) coupling constants and \(^{15}N\) chemical shifts. *Inorg. Chem.* **24**, 4685–4693 (1985).
23. Levason, W. & Fletcher. 195-Pt nuclear magnetic resonance spectroscopy. *Platin. Met. Rev.* **37**, 17–23 (1993).
24. Berg, J. M. Tymoczko, J. L., Stryer, *Biochemistry* (5th ed. Freeman, W. H.) (New York, 2002).
25. Pinto, A. L. & Lippard, S. J. Binding of the antitumor drug cis-diaminedichloroplatinum (II)(cisplatin) to DNA. *Acta Rev. Cancer* **780**, 167–180 (1985).
26. Lee, K. W. & Martin, D. S. Jr. Cis-dichlorodialamineplatinum (II). Aquation equilibria and isotopic exchange of chloride ligands with free chloride and tetrachloroplatinate (II). *Inorg. Chim. Acta* **24**, 4685–4693 (1985).
27. Yu, L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. *Adv. Drug Deliv. Rev.* **48**, 27–42 (2001).
28. Hagar, H., El Medany, A., Salam, R., El Medany, G. & Nayal, O. A. Betaine supplementation mitigates cisplatin-induced nephrotoxicity by abrogation of oxidative/nitrosative stress and suppression of inflammation and apoptosis in rats. *Exp. Toxicol. Pathol.* **67**, 133–141 (2015).

**Acknowledgements**

We thank Ms. S. Yamagishi (Hirata Laboratory) for her technical assistance. This study was partly supported by ACT-X (for K.K., JPMJAX1915 from Japan Science and Technology Agency), KAKENHI (18K14281 for K.K. and 17K07181 for E.H. from the Japan Society for the Promotion of Science), the Leading Initiative for Excellent Young Researchers (for K.K., from Ministry of Education, Culture, Sports, Science and Technology-Japan), and Kanazawa University SAKIGAKE project 2020.

**Author contributions**

R.K. and K.I. performed and analysed most of the biological experiments; R.K. and T.F performed NMR experiments; G.S. calculated the polarity of TMG; K.K., R.K., K.N., K.T. and E.H. cowrote the manuscript with input from all authors. All authors commented on the final manuscript and contributed to the interpretation of the results.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-89144-0.

**Correspondence** and requests for materials should be addressed to E.H. or K.K.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021